BioAge's BGE-102 Delivers Rapid and Significant Inflammation Reduction in Phase 1 Data—Promising Step Toward Cardiovascular Risk Therapy
Market Chameleon (Mon, 12-Jan 11:17 AM)
BioAge's BGE-102 Shows Robust Brain Penetration and 98% IL-1 Suppression in Positive Phase 1 Interim Data
Market Chameleon (Thu, 4-Dec 9:55 AM)
BioAge’s BGE-102 Achieves Strong Brain Penetration and 98% IL-1 Suppression in Interim Phase 1 Results
Market Chameleon (Thu, 4-Dec 9:42 AM)
